| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
Over the last 12 months, insiders at CASI Pharmaceuticals, Inc. have bought $0 and sold $0 worth of CASI Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at CASI Pharmaceuticals, Inc. have bought $5.34M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 33,300 shares for transaction amount of $142,627 was made by Huang James () on 2022‑09‑06.
| 2022-09-06 | Huang James | 33,300 0.2621% | $4.28 | $142,627 | -44.50% | |||
| 2022-08-31 | Huang James | 400 0.0029% | $3.74 | $1,497 | -40.27% | |||
| 2022-08-24 | Huang James | 39,527 0.2821% | $3.75 | $148,179 | -41.97% | |||
| 2022-08-19 | Huang James | 40,000 0.294% | $3.50 | $139,992 | -36.00% | |||
| 2022-06-13 | He Wei-Wu | Chairman and CEO | 2,096 0.0157% | $3.06 | $6,414 | -21.59% | ||
| 2021-11-18 | He Wei-Wu | Chairman and CEO | 200,000 0.1522% | $0.98 | $196,000 | -56.84% | ||
| 2021-11-17 | He Wei-Wu | Chairman and CEO | 200,000 0.1484% | $0.99 | $198,000 | -58.11% | ||
| 2021-08-19 | He Wei-Wu | Chairman and CEO | 180,000 0.0132% | $1.26 | $226,800 | -35.37% | ||
| 2021-08-18 | He Wei-Wu | Chairman and CEO | 300,000 0.0213% | $1.29 | $387,000 | -38.46% | ||
| 2021-03-26 | He Wei-Wu | Chairman and CEO | 3M 0.2392% | $2.05 | $6.15M | -42.48% | ||
| 2020-12-17 | Xu Weihao | Chief Financial Officer | 4,000 0.0003% | $2.63 | $10,537 | -41.82% | ||
| 2020-12-16 | Xu Weihao | Chief Financial Officer | 2,000 0.0002% | $2.44 | $4,880 | -39.85% | ||
| 2020-11-23 | He Wei-Wu | Chairman and CEO | 100,000 0.0082% | $2.18 | $218,000 | -27.78% | ||
| 2020-11-20 | He Wei-Wu | Chairman and CEO | 127,471 0.0104% | $2.12 | $270,239 | -26.24% | ||
| 2020-07-22 | He Wei-Wu | Chairman and CEO | 4.15M 0.3521% | $1.90 | $7.89M | +1.05% | ||
| 2020-07-22 | Zhang Larry | President | 20,153 0.0017% | $1.90 | $38,291 | +1.05% | ||
| 2020-05-20 | He Wei-Wu | Chairman and CEO | 56,464 0.0054% | $2.37 | $133,820 | -12.20% | ||
| 2020-05-19 | He Wei-Wu | Chairman and CEO | 29,801 0.0029% | $2.03 | $60,496 | +6.10% | ||
| 2020-05-18 | He Wei-Wu | Chairman and CEO | 338,932 0.0341% | $2.02 | $684,643 | +9.30% | ||
| 2020-05-15 | He Wei-Wu | Chairman and CEO | 100,000 0.0095% | $1.82 | $182,000 | +15.34% |
| IDG-Accel China Growth Fund III L.P. | 10 percent owner | 9126375 58.9076% | $12.41M | 2 | 0 | <0.0001% |
| SPARKLE BYTE LTD | 10 percent owner | 8498765 54.8566% | $11.56M | 1 | 0 | +3.48% |
| SPECTRUM PHARMACEUTICALS INC | director | 6897413 44.5204% | $9.38M | 5 | 0 | +27.02% |
| He Wei-Wu | Chairman and CEO | 594553 3.8376% | $808,592.08 | 31 | 0 | +28.31% |
| Huang James | 371517 2.398% | $505,263.12 | 4 | 0 | <0.0001% | |
| Burns James S | President and CEO | 185300 1.196% | $252,008.00 | 12 | 0 | +9.09% |
| Zhang Larry | President | 20153 0.1301% | $27,408.08 | 1 | 0 | +1.05% |
| Bair Kenneth Walter | SVP, Research and Development | 20000 0.1291% | $27,200.00 | 1 | 0 | |
| Hu Cynthia W. | COO | 17785 0.1148% | $24,187.60 | 4 | 0 | +67.61% |
| Ren Ken | CEO and Director | 15000 0.0968% | $20,400.00 | 1 | 0 | +67.61% |
| Ren Ken Keyong | CEO and Director | 15000 0.0968% | $20,400.00 | 1 | 0 | +67.61% |
| Xu Weihao | Chief Financial Officer | 10000 0.0645% | $13,600.00 | 2 | 0 | <0.0001% |
| SAGLIO DANE R | Chief Financial Officer | 7300 0.0471% | $9,928.00 | 2 | 0 | |
| KLEIN UDO | Senior Vice President of R&D | 1800 0.0116% | $2,448.00 | 1 | 0 | +66.23% |
CASI Pharmaceuticals, Inc. (CASI) | $53,490,060 | 55 | 19.35% | $21.07M |
$17,168,388 | 54 | -43.55% | $25.41M | |
$6,204,522 | 45 | 1.91% | $21.54M | |
$383,884 | 32 | -25.10% | $17.54M | |
$94,084,626 | 29 | -21.08% | $24.27M | |
$1,995,470 | 22 | 14.01% | $18.16M | |
$139,007,129 | 16 | 47.16% | $24.13M | |
$25,487,383 | 15 | -4.37% | $24.06M | |
$79,536,861 | 15 | -6.81% | $23.28M | |
$11,247,055 | 15 | -26.49% | $17.36M | |
$1,199,157 | 14 | 7.52% | $23.23M | |
$105,917 | 11 | -28.06% | $19.92M | |
$456,220 | 9 | 34.12% | $20.24M | |
$5,574,954 | 8 | -0.97% | $21.04M | |
$26,000,000 | 5 | -56.00% | $22.8M | |
$82,917 | 4 | -11.54% | $19.48M | |
$5,045,759 | 4 | -11.33% | $23.61M | |
$245,940 | 2 | 31.12% | $17.83M | |
$30,190 | 1 | -42.39% | $20.89M |
| Increased Positions | 8 | +38.1% | 94,955 | +3.57% |
| Decreased Positions | 4 | -19.05% | 8,731 | -0.33% |
| New Positions | 3 | New | 21,283 | New |
| Sold Out Positions | 2 | Sold Out | 12 | Sold Out |
| Total Postitions | 25 | +19.05% | 3M | +3.24% |
| Foresite Capital Management Vi Llc | $2,592.00 | 8.86% | 1.33M | +1M | New | 2024-12-31 |
| Vr Adviser, Llc | $1,925.00 | 6.58% | 987,259 | 0 | 0% | 2024-12-31 |
| Woodline Partners Lp | $194.00 | 0.67% | 99,690 | +69,158 | +226.51% | 2024-12-31 |
| Wellington Shields Capital Management, Llc | $167.00 | 0.57% | 85,835 | -3,382 | -3.79% | 2024-12-31 |
| Adar1 Capital Management, Llc | $90.00 | 0.31% | 46,320 | -18,515 | -28.56% | 2024-12-31 |
| Renaissance Technologies Llc | $77.00 | 0.26% | 39,400 | -2,100 | -5.06% | 2024-12-31 |
| Wellington Shields & Co., Llc | $59.00 | 0.2% | 30,091 | -13,000 | -30.17% | 2024-12-31 |
| Geode Capital Management, Llc | $38.00 | 0.13% | 19,363 | 0 | 0% | 2024-12-31 |
| Ubs Group Ag | $22.00 | 0.08% | 11,308 | -3,373 | -22.98% | 2024-12-31 |
| Royal Bank Of Canada | $13.00 | 0.05% | 6,900 | 0 | 0% | 2024-12-31 |